Top ETFs Tracking CRISPR Gene Editing

These exchange-traded funds track companies in this biotech space.

By Keith Speights – Updated Oct 31, 2025 at 10:52 PM | Fact-checked by Frank Bass

Key Points

CRISPR ETFs invest in companies perfecting gene-editing technology, potentially key for future disease treatments.
Top CRISPR ETFs include ARK Genomic Revolution, Global X Genomics, and WisdomTree BioRevolution Fund.
Investing in CRISPR ETFs offers potential high returns but comes with high volatility and expense ratios.

By now, many investors have probably heard enough about CRISPR (clustered regularly interspaced short palindromic repeats) to be relatively familiar with the idea. But some may not be familiar with the exchange-traded funds (ETFs) tracking gene-editing stocks. CRISPR ETFs own the stocks of companies focusing on CRISPR gene editing.

DNA with a small section separated from the main part. — Image source: Getty Images.

Gene-editing technology has the potential to change the treatment of many diseases by modifying DNA to correct mutations. CRISPR could even cure diseases in some cases. The ETFs that own the best CRISPR stocks could be big winners for investors over the long run.

Best CRISPR and gene-editing ETFs

Quite a few biotech ETFs are available for investors to buy. The number of CRISPR and gene-editing ETFs, however, is more limited. Here are the top five ETFs that focus on CRISPR gene editing.

Data source: ETF websites as of June 13, 2025. ETF = exchange-traded fund.
ETF and Ticker	Expense Ratio
ARK Genomic Revolution ETF (NYSEMKT:ARKG)	0.75%
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)	0.5%
Invesco Dynamic Biotechnology & Genome ETF (NYSEMKT:PBE)	0.58%
iShares Genomics Immunology and Healthcare ETF (NYSEMKT:IDNA)	0.47%
Wisdom Tree BioRevolution Fund (BATS:WDNA)	0.45%

Loading paragraph...

4. iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF attempts to track an index of companies in developed and emerging markets that focus on genomics, immunology, and bioengineering. It currently owns positions in 44 pharmaceutical and biotech stocks.

This ETF's holdings include four previously mentioned stocks with CRISPR gene-editing ties that are owned by the other ETFs on the list: CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Regeneron Pharmaceuticals.

5. WisdomTree BioRevolution Fund

The WisdomTree BioRevolution Fund seeks to track the performance of an index consisting of companies that "will be significantly transformed by advancements in genetics and biotechnology." Like the other ETFs discussed, it doesn't limit itself to only CRISPR or gene-editing stocks.

This fund owns several CRISPR gene-editing stocks that are in the previously mentioned portfolios: Beam Therapeutics, CRISPR Therapeutics, Gilead Sciences, Intellia Therapeutics, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Verve Therapeutics. It also owns shares of AstraZeneca (AZN -1.50%) and Caribou Biosciences (CRBU -3.58%), both of which are developing CRISPR gene editing therapies.

Pros and cons of investing in CRISPR ETFs

The pros of investing in CRISPR ETFs include:

Significant long-term potential for CRISPR technology
Diversification across multiple stocks focused on CRISPR gene editing
Less research is required than trying to select individual CRISPR stocks

However, there are some cons of investing in these ETFs as well, including:

High risk and volatility
Relatively high expense fees

FAQ

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Gilead Sciences, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.